Good news in the eye treatment market! Involving ophthalmic injections, medical products...

【Pharmaceutical Network Industry News】With the aging development of China's population and the widespread use of electronic products, the incidence of eye diseases is continuing to increase
.
Affected by this, the scale of the ophthalmic medical market has also begun to show a steady growth trend
.
According to the China Business Industry Research Institute, the market size of ophthalmic drugs in China reached US$2.
8 billion
in 2020.
At present, with its steady growth, the ophthalmic treatment market has become the key area
of the strategic layout of many pharmaceutical companies at home and abroad.
Recently, many companies have ushered in good news in
this field.
For example, on November 15, Kanghong Pharmaceutical issued an announcement that KH631 ophthalmic injection declared by its subsidiary Hongji Biotech obtained the drug clinical trial approval notice from the China Medical Products Administration and agreed to carry out clinical trials
.
It is understood that KH631 ophthalmic injection is a new generation of ophthalmic gene therapy products and Class 1 biological new drugs developed by Kanghong Pharmaceutical, with independent intellectual property rights
.
It is characterized by tissue specificity, immunogenicity, expression controllability and infection efficiency, and has shown sustained efficacy in preclinical disease models, which is expected to achieve the potential efficacy
of "once treated, cured for life".
It is worth mentioning that this is also the first gene therapy product
approved for the treatment of neovascular (wet) age-related macular degeneration (nAMD) in China.
The industry believes that the future market prospects of the drug are huge
.
This follows Zhaoke Ophthalmology announced that it has entered into an exclusive distribution agreement
for TONO-i in Greater China with South Korean company C&V Tech.
Zhaoke Ophthalmology said that TONO-i will be an important part of the company's glaucoma medical product portfolio to fill the demand gap
of low diagnosis and treatment rates in China.
In addition, on November 10, the Class 5.
1 new drug levofloxacin dexamethasone eye drops introduced by Zhaoke Ophthalmology have also been declared for marketing
in China.
It is reported that this is an innovative drug with the code NTC010 introduced by Zhaoke Ophthalmology from NTC Company, which is intended to be developed for the prevention and treatment of inflammation and infection
after cataract surgery.
It is worth mentioning that at this Expo, many pharmaceutical companies have also brought new products
in ophthalmic treatment.
For example, Carl Zeiss (Shanghai) Management Co.
, Ltd.
's new product "ZERISS ARTEVO 800 Ophthalmic Navigation Surgical Microscope" (hereinafter referred to as "ZEISS ARTEVO 800") was officially launched at the meeting
.
Subsequently, on the afternoon of November 6th, ZEISS and Chengdu Puri Eye Hospital Co.
, Ltd.
successfully held a cooperation signing ceremony at the Expo, and the two sides reached a cooperation
on five ZEISS ARTEVO 800 ophthalmic navigation surgical microscopes.
In addition, Alcon also brought a physical therapy - Systane iLux® MGD treatment system
at this Expo.
The Systane iLux® MGD treatment system, like Johnson & Johnson's exhibitors, is a physical therapy
for meibomian gland dysfunction.
.
.
.
.
.
.
In general, in order to meet the vast and continuous market demand for ophthalmic treatment, many domestic and foreign companies are increasing their layout in this field and are constantly ushering in new breakthroughs
.
In the future, the industry expects that with the efforts of many enterprises, the track will enter a stage of rapid development, and at the same time, with the continuous progress of basic research, the ophthalmic treatment market will gradually enter the era of
innovation.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.